Current opinion in pharmacology, 2014-02, Vol.14, p.18-22
2014
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Preventing cognitive decline in preclinical Alzheimer's disease
- Ist Teil von
- Current opinion in pharmacology, 2014-02, Vol.14, p.18-22
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2014
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • Preclinical Alzheimer's disease is common and can be diagnosed by CSF markers. • Preclinical AD and future cognitive decline and mortality are strongly associated. • Delay of onset of cognitive impairment in preclinical AD is a therapeutic target. • Subtle cognitive deficits can be remotely assessed using modern digital platforms. • A public–private collaborative approach may be required for AD prevention trials.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1471-4892eISSN: 1471-4973DOI: 10.1016/j.coph.2013.10.002Titel-ID: cdi_proquest_miscellaneous_1544018378
- Format
- –
- Schlagworte
- Aged, Alzheimer Disease - diagnosis, Alzheimer Disease - physiopathology, Alzheimer Disease - prevention & control, Amyloid beta-Peptides - metabolism, Biomarkers - metabolism, Brain - physiopathology, Clinical Trials as Topic - methods, Cognition Disorders - etiology, Cognition Disorders - prevention & control, Cooperative Behavior, Dementia - diagnosis, Dementia - etiology, Dementia - prevention & control, Disease Progression, Humans, Internal Medicine, Medical Education